Sign In To Continue
You have reached the guest article limit.
Unlock more of the IIPLA newsroom by signing in with SSO or joining as a member.
The U.S. Supreme Court has opted not to take up Purdue Pharma’s appeal concerning patent litigation over its opioid medication OxyContin. This decision means that prior rulings against Purdue in the patent dispute remain in effect, potentially impacting the company’s control over the drug’s intellectual property right…
Share This Article
Ready-to-post copy includes the article link.
Supreme Court Declines to Review Purdue Pharma’s OxyContin Patent Dispute The U.S. Supreme Court has opted not to take up Purdue Pharma’s appeal concerning patent litigation over its opioid medication OxyContin. This decision means that prior rulings against Purdue in the patent dispute remai... Read the full IIPLA article: https://iipla.org/news/supreme-court-declines-to-review-purdue-pharma-s-oxycontin-patent-dispute